Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE)...
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE)...
Study finds that despite past headlines, COVID-19 infection rates are higher amongst people of color.Washington, D.C.--(Newsfile Corp. - December 20,...
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on...
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (āCocrystalā or the āCompanyā), announces the presentation...
SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (āCocrystalā or the āCompanyā) announces that James...
SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new...
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleLONDON, Ontario and...
SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (āJunshi Biosciences,ā HKEX: 1877; SSE: 688180), a...
ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (āEmergexā), a clinical-stage biotechnology company addressing major...
Proceeds Will be Utilized to Pay Down All Unsecured Debt and Approximately 45% of Secured Debt UpHealth Will Focus on...
SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed...
The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to ProgressPlanning for APVO436 Phase 2...
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of...
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
The thyroid hormone receptor-beta (THR-b) drug ALG-055009: Was well tolerated when oral daily doses up to 1.0 mg were given...
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ----...
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to...